Drug Profile
Research programme: NOV C-ter - Sisene Biotechnology
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator CNRS; INSERM
- Developer Sisene Biotechnology
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors; Endothelial cell modulators; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders; Inflammation; Solid tumours
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Eye-disorders in France (Ophthalmic)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in France (Parenteral)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Solid-tumours in France (Parenteral)